| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
20,430,000 |
| Market
Cap: |
1.36(B) |
| Last
Volume: |
2,387,520 |
Avg
Vol: |
2,380,857 |
| 52
Week Range: |
$37.29 - $69.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ANI Pharmaceuticals is a bio-pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include: Candesartan Hydrochlorothiazide, Fenofibrate, Fluvoxamine, Hydrocortisone Enema, Lithium Carbonate ER, Mesalamine, Propranolol ER, Terbutaline, and Vancomycin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
230,132 |
422,694 |
1,171,108 |
1,389,174 |
| Total Sell Value |
$15,188,297 |
$25,482,465 |
$68,628,084 |
$77,001,153 |
| Total People Sold |
8 |
9 |
11 |
11 |
| Total Sell Transactions |
20 |
41 |
78 |
81 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-07-21 |
4 |
AS |
$52.56 |
$604,440 |
I/I |
(11,500) |
1,232,620 |
|
-4% |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-07-20 |
4 |
AS |
$51.52 |
$309,120 |
I/I |
(6,000) |
1,244,120 |
|
-1% |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-07-19 |
4 |
AS |
$51.48 |
$307,284 |
I/I |
(5,969) |
1,250,120 |
|
1% |
|
| Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
• – – |
2023-07-18 |
4 |
D |
$51.89 |
$90,444 |
D/D |
(1,743) |
37,799 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-07-18 |
4 |
AS |
$51.84 |
$347,328 |
I/I |
(6,700) |
1,256,089 |
|
-0% |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-07-17 |
4 |
AS |
$51.06 |
$501,971 |
I/I |
(9,831) |
1,262,789 |
|
1% |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-07-14 |
4 |
AS |
$50.43 |
$504,300 |
I/I |
(10,000) |
1,272,620 |
|
2% |
|
| Gassert Chad |
SVP - CORP. DEV. & STRATEGY |
• – – |
2023-07-03 |
4 |
AS |
$53.43 |
$1,068,600 |
I/I |
(20,000) |
353,226 |
|
1% |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-06-23 |
4/A |
AS |
$51.49 |
$514,900 |
I/I |
(10,000) |
1,282,620 |
|
- |
|
| Gassert Chad |
SVP - CORP. DEV. & STRATEGY |
• – – |
2023-06-22 |
4 |
AS |
$51.32 |
$1,026,400 |
I/I |
(20,000) |
373,226 |
|
17% |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-06-22 |
4/A |
AS |
$51.38 |
$693,630 |
I/I |
(13,500) |
1,292,620 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-06-22 |
4 |
AS |
$51.38 |
$693,630 |
D/D |
(13,500) |
7,407 |
|
17% |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-06-21 |
4/A |
AS |
$51.95 |
$615,244 |
I/I |
(11,843) |
1,306,120 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-06-21 |
4 |
AS |
$51.95 |
$615,244 |
D/D |
(11,843) |
20,907 |
|
13% |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-06-20 |
4/A |
AS |
$51.93 |
$761,138 |
I/I |
(14,657) |
1,317,963 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-06-20 |
4 |
AS |
$51.93 |
$761,138 |
D/D |
(14,657) |
32,750 |
|
15% |
|
| Tannenbaum Renee P |
Director |
– • – |
2023-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,865 |
20,211 |
|
- |
|
| Nash David |
Director |
– • – |
2023-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,865 |
38,561 |
|
- |
|
| Thoma Jeanne |
Director |
– • – |
2023-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,865 |
36,199 |
|
- |
|
| Pera Antonio R |
Director |
– • – |
2023-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,865 |
36,627 |
|
- |
|
| Walsh Patrick D |
Director |
– • – |
2023-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,865 |
70,302 |
|
- |
|
| Haughey Thomas |
Director |
– • – |
2023-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,865 |
47,116 |
|
- |
|
| Carey Stephen P. |
SVP & CFO |
• – – |
2023-04-10 |
4 |
D |
$38.50 |
$174,559 |
D/D |
(4,534) |
173,478 |
|
- |
|
| Marken James G. |
SVP OPS & PROD DEV |
• – – |
2023-04-10 |
4 |
D |
$38.50 |
$88,127 |
D/D |
(2,289) |
131,627 |
|
- |
|
| Marken James G. |
SVP OPS & PROD DEV |
• – – |
2023-03-28 |
4 |
D |
$38.62 |
$20,237 |
D/D |
(524) |
112,206 |
|
- |
|
399 Records found
|
|
Page 5 of 16 |
|
|
0.52 (0.79%) 
